In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't usability alone—it's making it easier for patients and sites to interact more effectively with each other.
Commentary|Videos|February 5, 2025
SCOPE Summit 2025: Veeva’s Drew Garty Discusses Pragmatic Clinical Trials
Author(s)Andy Studna, Senior Editor
In an interview with ACT senior editor Andy Studna at SCOPE Summit, Garty, chief technology officer, clinical data, provided his key takeaways from a panel he participated in on the growing interest around pragmatic studies.
Advertisement
ACT: What are some of your key takeaways from the panel you participated in on pragmatic trials?
Garty: Going in, pragmatic trials really talk about the delta that we have, I think, between the traditional clinical research that we have in the real world, and there's a gap that when you go through that you prove efficacy in a controlled environment, that doesn't actually mean that you are set up for success in the real world. There's a lot of policy that actually has to be changed in terms of recommendations of which therapies to treat with, so we need to bring in if we want to close the gap between when a Phase III trial ends and hospitals start administering the use of the products, we actually have to close that gap down. In a way, pragmatic trials are then feeding upstream into Phase III trials and giving us the ability to simplify and standardize what we do. A good example of reducing the costs and complexities of protocols, decreasing the amount of procedures a patient might have to endure, and even where they are in the world. All of those things can be addressed with what we have in terms of tools and capabilities, but we need to focus as an industry.
Advertisement
Related to this article
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation—from building trust between patients and sites to where AI may and may not have a role in that relationship.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, outlines what it takes to move beyond transactional engagement and treat patient advocacy organizations as long-term partners in the science and the care.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, describes how shifting patient engagement from protocol review to endpoint selection transforms both the quality of trial data and the experience of participation.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.
In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explain how ICH E6(R3) and new empirical evidence of RBQM's net financial impact give sponsors the tools they need to build the multi-functional buy-in required for successful adoption—and why RBQM only delivers full value when it replaces, not supplements, traditional monitoring.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
How a Platform Approach Can Scale AI’s Impact in Life Sciences
2
Four Years After Disrupting Clinical Trial Diversity at DPHARM, Acclinate Is Back to Disrupt the Data Behind It
3
DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now
4
DPHARM 2026: Why Making Technology Easier Isn't Enough for Sites
5